Synthesis and in vivo evaluation of [O‐methyl‐11C] 2‐(4‐methoxyphenyl)‐N‐(4‐methylbenzyl)‐N‐(1‐methyl‐ piperidin‐4‐yl)acetamide as an imaging probe for 5‐HT2A receptors

doi:10.1002/JLCR.1124

Paper

Synthesis and in vivo evaluation of [O‐methyl‐11C] 2‐(4‐methoxyphenyl)‐N‐(4‐methylbenzyl)‐N‐(1‐methyl‐ piperidin‐4‐yl)acetamide as an imaging probe for 5‐HT2A receptors

Published Oct 30, 2006 · J. Prabhakaran, R. Parsey, V. J. Majo

Journal of Labelled Compounds and Radiopharmaceuticals

Q3 SJR score

2

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)acetamide (AC90179, 4), a highly potent and selective competitive 5-HT2A antagonist, was labeled by [11C]-methylation of the corresponding desmethyl analogue 5 with [11C]methyl triflate. The precursor molecule 5 for radiolabeling was synthesized from p-tolylmethylamine in three steps with 46% overall yield. [11C]AC90179 was synthesized in 30 min (30 ± 5% yield, EOS) with a specific activity of 4500 ± 500 Ci/mmol and >99% chemical and radiochemical purities. Positron emission tomography studies in anesthetized baboon revealed that [11C]4 Penetrates the blood–brain barrier (BBB) with a rapid influx and efflux of the tracer in all brain regions. Due to lack of tracer retention or specific binding, [11C]4 cannot be used as PET ligand for imaging 5-HT2A receptors. Copyright © 2006 John Wiley & Sons, Ltd.

Non-RCT

Animal Study

Study Snapshot

[O-methyl-11C] 2(4-methoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)acetamide (AC90179) shows potential as a PET ligand for imaging 5-HT2A receptors

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Synthesis and in vivo evaluation of [O‐methyl‐11C] 2‐(4‐methoxyphenyl)‐N‐(4‐methylbenzyl)‐N‐(1‐methyl‐ piperidin‐4‐yl)acetamide as an imaging probe for 5‐HT2A receptors

Sign up to use Study Snapshot

References

Binding characteristics of the 5‐HT2A receptor antagonists altanserin and MDL 100907

Altanserin and MDL 100907 show similar binding characteristics in rat brain, with [18F]altanserin showing greater selectivity for the 5HT2A receptor.

A positron emission tomography study of the effects of treatment with valproate on brain 5-HT2A receptors in acute mania.

Valproate treatment for acute manic patients does not significantly affect brain 5-HT2A receptor binding, but 5-HT2A receptor involvement in downstream signaling pathways remains possible.

Pharmacological Characterization of AC-90179 [2-(4-Methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide Hydrochloride]: A Selective Serotonin 2A Receptor Inverse Agonist

AC-90179 shows high potency as an inverse agonist and competitive antagonist at serotonin receptors, with potential for treating psychosis with increased oral bioavailability.

Drug therapy in schizophrenia.

Atypical antipsychotic agents are more effective and safer than conventional drugs, but require ongoing treatment to prevent relapse.

Pathophysiology of antipsychotic drug-induced movement disorders.

Atypical antipsychotic agents may have fewer drug-induced movement disorders than conventional agents due to their greater activity in blocking serotonin-2A receptors and shorter blockade of dopamine-2 receptors.

Citations

Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.

Serotonin receptor PET ligands are essential tools in clinical diagnosis and drug discovery, aiding in understanding neuropsychiatric disorders and neurodegenerative diseases.